Free Trial
NASDAQ:TNGX

Tango Therapeutics Q2 2023 Earnings Report

Tango Therapeutics logo
$1.51 +0.10 (+7.09%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.37 -0.14 (-9.27%)
As of 05/2/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tango Therapeutics EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Tango Therapeutics Revenue Results

Actual Revenue
$14.60 million
Expected Revenue
$7.00 million
Beat/Miss
Beat by +$7.60 million
YoY Revenue Growth
N/A

Tango Therapeutics Announcement Details

Quarter
Q2 2023
Time
Before Market Opens
Conference Call Date
Monday, August 7, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Tango Therapeutics' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tango Therapeutics Earnings Headlines

Barbara Weber, M.D., Elected to ITM Supervisory Board
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Barclays Sticks to Its Buy Rating for Tango Therapeutics (TNGX)
Tango Therapeutics (TNGX) Receives a Buy from Barclays
See More Tango Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tango Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tango Therapeutics and other key companies, straight to your email.

About Tango Therapeutics

Tango Therapeutics (NASDAQ:TNGX), a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

View Tango Therapeutics Profile

More Earnings Resources from MarketBeat